2026-08-10

[2026-08-10] ingest | omega-3 and skeletal muscle — mechanistic claims vs pooled evidence

Source: a Physionic YouTube video (“The Unexpected Muscle Effect of… Omega-3 Fats?”), mined per scraping-youtube-references as a lead list only. The video is not cited anywhere in the wiki. Its description carried five primary references; all five were resolved to DOI/PMID via Crossref and Europe PMC, and the transcript’s claims were checked against the papers rather than accepted as framed.

Why this was a real gap

omega-3-fatty-acids was verified and detailed as of 2026-08-04 but carried zero skeletal-muscle coverage, and sarcopenia carried zero omega-3 coverage — despite muscle being the family’s most-promoted aging application after cardiovascular risk. The video’s references are all 2011–2019; a date-filtered PubMed search surfaced a substantial 2020–2026 meta-analytic literature that materially changes the conclusion.

Pages added

Five study pages, seeded in parallel:

• smith-2011-omega3-muscle-protein-synthesis-older-adults — RCT, n=16 older adults, 8 wk. Verified against PMC open full text. Basal muscle protein synthesis unchanged (P=0.80); only the hyperaminoacidemic–hyperinsulinemic clamp response was augmented (P<0.01).
• smith-2015-omega3-muscle-mass-function-older-adults — RCT, n=60 randomized / 44 completed, 6 mo. Verified against PMC open full text. Thigh muscle volume +3.6% (95% CI 0.2–7.0%), handgrip +2.3 kg, 1-RM +4.0%; isokinetic power null (P=0.075).
• rodacki-2012-fish-oil-strength-training-elderly-women — RCT, n=45 women ~64 y, no placebo arm. Closed access, abstract-only (#gap/no-fulltext-access). The origin of most “omega-3 acts on the motor unit” claims.
• therdyothin-2025-omega3-protein-synthesis-meta-analysis — the pivotal negative synthesis. Muscle protein synthesis null across k=6 (SMD 0.03, 95% CI −0.35 to 0.40); whole-body protein synthesis positive on only k=3.
• santo-andre-2023-n3pufa-muscle-meta-analysis — 14 studies, n=1,443. No mass effect, no function effect, very small strength effect (SMD 0.12, 95% CI 0.006–0.24) against high risk of bias.

Corrections to the video’s framing

Three claims in the transcript did not survive checking against the primary sources:

1. “Omega-3 stimulates muscle protein synthesis.” Both Smith trials show basal synthesis unchanged; only the amino-acid/insulin-stimulated increment rose. The accurate statement is enhancement of the response to anabolic stimulation, not unconditional stimulation. This matters because one relevant sarcopenia lesion is anabolic resistance.
2. “The mitochondrial membrane does not change.” True only of total mitochondrial phospholipid abundance. In fatty-acid composition, Gerling 2019 (verified against PMC full text) shows mitochondria remodeled substantially (EPA/DHA ~3-fold, omega-6:omega-3 ratio down P<0.001, unsaturation index +14%), while the sarcolemma was the least responsive compartment (EPA unchanged; ratio and unsaturation index unaltered). Note the paper cautions that fractions use different normalization denominators, so compartments can be ranked for responsiveness but not absolute magnitude — an earlier draft of this page overstated this as mitochondria remodeling “most,” which the review corrected.
3. Reactive-oxygen-species teaser. Herbst 2014 reported increased mitochondrial ROS emission capacity explicitly without any rise in oxidative-damage products. Presenting this as evidence of omega-3-induced oxidative injury reverses the paper’s own conclusion.

The video’s own caveats about missing placebo controls were, if anything, understated: Gerling 2019, Herbst 2014, and Smith 2011 Clinical Science are all uncontrolled single-arm designs, and Rodacki 2012 had no placebo capsule.

The recency finding — and a major self-correction

The first draft of this synthesis concluded that “the mechanism does not survive pooling.” That was wrong, and an adversarial Codex review (gpt-5.6-sol, xhigh, read-only) caught it. Two errors, both confirmed by me against primary full text before rewriting:

1. Estimand conflation. Therdyothin 2025’s headline null (SMD 0.03, k=6) pooled basal fractional synthetic rate — the paper explicitly selected the basal value from the one trial reporting both. Basal is exactly where the Smith trials also found nothing, so the pooled null does not contradict them. The stimulated-state analyses, which actually test sensitization, were directionally positive but underpowered and imprecise: SMD 0.41 (95% CI −0.16 to 0.98, k=3) and SMD 0.52 (95% CI −0.64 to 1.67, k=4). Correct framing: the sensitization hypothesis is unconfirmed, not refuted. The “positive outliers” language was also unjustified — no outlier analysis was performed and Smith’s positive estimand was never in the main pool.
2. A false universal claim. “No effect in any major synthesis” for muscle mass was factually wrong. Huang 2020 (Nutrients 12(12):3739) found +0.33 kg (95% CI 0.05–0.62), rising to +0.67 kg above 2 g/day. It was in my own search results and I skipped it. Corrected to “no consistent pooled effect,” with the dissent visible.

The review also correctly flagged that “concentrated in the lower body” is defeated by Tseng’s (imprecise) upper-extremity estimate; that Gerling does not license ranking mitochondria above whole muscle for remodeling, since the fractions use different normalization denominators (the “inverted” language was removed, while the authors’ own “sarcolemma least responsive” framing was kept); and that non-significant moderator tests were being read as evidence of equivalence.

Net effect: the section is now less negative and better calibrated. The pooled nulls are failures to detect in small, high-risk-of-bias literatures — they constrain confident claims of benefit without establishing absence of effect. A dose-response above ~2 g/day is a live hypothesis, not a settled null. Null protein synthesis alongside real strength gains is also not a contradiction: strength can improve via neural drive or contractile quality without hypertrophy.

Propagation

• omega-3-fatty-acids — new ## Skeletal muscle, sarcopenia, and the neuromuscular unit section (anabolic sensitization; compartment-specific membrane incorporation; clinical-outcomes table; neuromuscular unit; bottom line), plus a new row in the human-evidence matrix, 11 new footnotes, and cross-references. literature-checked-through refreshed to 2026-08-10; verified-scope amended to record exactly which of the new sources were full-text-verified versus abstract-only.
• sarcopenia — new ### Omega-3 fatty acids — weak, mass-null subsection under Interventions, placed below resistance training, protein/leucine, and vitamin D to reflect its evidence rank.

Wikilink resolution checked across all five new pages (no dangling targets); public-repo leak gate run clean, including a direct scan of the untracked new files that the diff-scoped check does not cover.